Avantor Acquires VWR
Avantor Inc. has completed the acquisition of VWR Corporation for an approximate amount of $6.5 billion.
Avantor Inc. has completed the acquisition of VWR Corporation for an approximate amount of $6.5 billion. A global provider of product, supply chain, and service solutions to laboratory and production customers, VWR will continue on as a subsidiary of Avantor with Michael Stubblefield, the current Chief Executive Officer of Avantor, leading the combined company.
“The completion of this acquisition marks the beginning of an exciting new chapter for our combined organization,” said Stubblefield.
“With enhanced scale and favourable long-term industry dynamics, we are well positioned to accelerate growth, benefiting from deeper access to the high-growth biopharma, industrial, and applied research sectors,” continued Stubblefield.
Manuel Brocke-Benz, former Chief Executive Officer of VWR, added, “By executing on our business plan and growth strategy, VWR built a truly differentiated company, with broad global distribution capabilities and a breadth of essential products, services, and technology offerings for laboratory and production customers around the world. I have every confidence that combining VWR with Avantor’s expertise in high-purity materials will enable the new organization to even better meet our global customers’ evolving needs.”
Despite its acquisition, the name VWR will continue with Avantor acting as the corporate name of the new company to ensure a smooth transition and allow customers to continue to order from the VWR website as they always have.
For more information please visit www.settingscienceinmotion.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
